Compare Adaptive Biotechnologies Corp (ADPT) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Citius Pharmaceuticals Inc — how do they compare? Adaptive Biotechnologies Corp trades at $19.94 (market cap $3.33B), while Citius Pharmaceuticals Inc trades at $0.56 (market cap $15.98M). The key difference: Adaptive Biotechnologies Corp is far larger — about 208.4× Citius Pharmaceuticals Inc's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | CTXR | |
|---|---|---|
Market Cap | $3.33B | $15.98M |
Sector | Health | Health |
52-Week High | $22.37 | $1.94 |
52-Week Low | $10.24 | $0.53 |
Enterprise Value | $3.19B | $12.19M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
CTXR trades at $0.6075, up 5.73% in the last session, with a neutral technical signal and bearish moving averages. The company reported a net loss of $37.43 million for 2025, with a negative net income margin of -823.34%, while generating $5.6 million in revenue in the first half of 2026 from its LYMPHIR launch. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO, though earnings have consistently missed expectations.
The outlook remains speculative, with significant upside potential if LYMPHIR gains commercial traction, but high execution risks and persistent losses pose substantial downside. Analyst consensus is strongly bullish at 83.3% buy ratings, reflecting optimism on the drug pipeline, yet investors face dilution risks from recent financing and the challenge of achieving profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
